Ask AI
MARIPOSA
MARIPOSA: Final Overall Survival of First-line Amivantamab + Lazertinib vs Osimertinib for Untreated EGFRm Advanced NSCLC

Released: April 10, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: April 10, 2025